EP1689354A2 - Amelioration of cataracts, macular degeneration and other ophthalmic diseases - Google Patents
Amelioration of cataracts, macular degeneration and other ophthalmic diseasesInfo
- Publication number
- EP1689354A2 EP1689354A2 EP04812275A EP04812275A EP1689354A2 EP 1689354 A2 EP1689354 A2 EP 1689354A2 EP 04812275 A EP04812275 A EP 04812275A EP 04812275 A EP04812275 A EP 04812275A EP 1689354 A2 EP1689354 A2 EP 1689354A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- eye
- alkenyl
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 36
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 48
- 201000010099 disease Diseases 0.000 title claims description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 155
- 239000000203 mixture Substances 0.000 claims abstract description 107
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 34
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 27
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 25
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 23
- 238000011161 development Methods 0.000 claims abstract description 23
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 17
- 201000010041 presbyopia Diseases 0.000 claims abstract description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 17
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 16
- 206010046851 Uveitis Diseases 0.000 claims abstract description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 128
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 210000001519 tissue Anatomy 0.000 claims description 43
- -1 sulfhydryl compound Chemical class 0.000 claims description 27
- 239000003889 eye drop Substances 0.000 claims description 26
- 239000012530 fluid Substances 0.000 claims description 21
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 19
- 239000003638 chemical reducing agent Substances 0.000 claims description 18
- 230000006378 damage Effects 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- 229940012356 eye drops Drugs 0.000 claims description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 208000010217 blepharitis Diseases 0.000 claims description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 10
- 229960004308 acetylcysteine Drugs 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 201000004700 rosacea Diseases 0.000 claims description 9
- 108010024636 Glutathione Proteins 0.000 claims description 8
- 229960003180 glutathione Drugs 0.000 claims description 8
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 5
- 108010058907 Tiopronin Proteins 0.000 claims description 5
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000003885 eye ointment Substances 0.000 claims description 5
- 229960004402 tiopronin Drugs 0.000 claims description 5
- 206010072139 Ocular rosacea Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 210000003780 hair follicle Anatomy 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 229940069265 ophthalmic ointment Drugs 0.000 claims description 2
- 208000016134 Conjunctival disease Diseases 0.000 claims 2
- 208000029728 Eyelid disease Diseases 0.000 claims 2
- 208000024963 hair loss Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 1
- 208000021921 corneal disease Diseases 0.000 abstract description 6
- 208000022873 Ocular disease Diseases 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 210000001508 eye Anatomy 0.000 description 117
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 64
- 210000000695 crystalline len Anatomy 0.000 description 51
- CSGAUKGQUCHWDP-UHFFFAOYSA-N 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)N1O CSGAUKGQUCHWDP-UHFFFAOYSA-N 0.000 description 43
- 241000283973 Oryctolagus cuniculus Species 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 36
- 238000011282 treatment Methods 0.000 description 35
- 239000007787 solid Substances 0.000 description 33
- 210000004087 cornea Anatomy 0.000 description 32
- 150000002148 esters Chemical class 0.000 description 31
- 239000007924 injection Substances 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- 229940125904 compound 1 Drugs 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000018109 developmental process Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 210000001742 aqueous humor Anatomy 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 16
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 230000000699 topical effect Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 14
- 230000002207 retinal effect Effects 0.000 description 14
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 13
- 206010013774 Dry eye Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 12
- 210000001525 retina Anatomy 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 10
- 210000000744 eyelid Anatomy 0.000 description 10
- 150000002443 hydroxylamines Chemical class 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 208000001351 Epiretinal Membrane Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000032050 esterification Effects 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 8
- 206010057430 Retinal injury Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000004817 gas chromatography Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004410 intraocular pressure Effects 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 208000001344 Macular Edema Diseases 0.000 description 6
- 208000031471 Macular fibrosis Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- 206010058202 Cystoid macular oedema Diseases 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- 238000004435 EPR spectroscopy Methods 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 201000010206 cystoid macular edema Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 238000011587 new zealand white rabbit Methods 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 210000003786 sclera Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 241001303601 Rosacea Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940001584 sodium metabisulfite Drugs 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001585 trabecular meshwork Anatomy 0.000 description 4
- 210000001745 uvea Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 206010011005 corneal dystrophy Diseases 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000554 iris Anatomy 0.000 description 3
- 238000002430 laser surgery Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000004173 Epithelial basement membrane dystrophy Diseases 0.000 description 2
- 208000020564 Eye injury Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010022557 Intermediate uveitis Diseases 0.000 description 2
- 201000002287 Keratoconus Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010069652 Retinal phototoxicity Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000001437 anti-cataract Effects 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000029233 macular holes Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008789 oxidative DNA damage Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 229940110150 xylazine 20 mg/ml Drugs 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- GTDXPJJHRWOFDI-UHFFFAOYSA-N 1-methylcyclopropane-1-carbonyl chloride Chemical compound ClC(=O)C1(C)CC1 GTDXPJJHRWOFDI-UHFFFAOYSA-N 0.000 description 1
- IELVZKKFWNCUAQ-UHFFFAOYSA-N 1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C=CN21 IELVZKKFWNCUAQ-UHFFFAOYSA-N 0.000 description 1
- LGPTVHABQNQBSK-UHFFFAOYSA-N 2,2-dimethyl-3-phenylmethoxypropanoic acid Chemical compound OC(=O)C(C)(C)COCC1=CC=CC=C1 LGPTVHABQNQBSK-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- ICRSDYDMKBXRSR-UHFFFAOYSA-N 2-(5-methoxynaphthalen-2-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2C(OC)=CC=CC2=C1 ICRSDYDMKBXRSR-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1C1CC(O)C(CO)O1 HCAJQHYUCKICQH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- MKSTVOHTVVVYHL-UHFFFAOYSA-N 3-acetyloxy-2,2-dimethylpropanoic acid Chemical compound CC(=O)OCC(C)(C)C(O)=O MKSTVOHTVVVYHL-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124428 anticataract agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 201000005668 blepharoconjunctivitis Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- UBWDBGWGZCHPHO-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.C1CCCCC1N=C=NC1CCCCC1 UBWDBGWGZCHPHO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000001151 non-parametric statistical test Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical class O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000009876 ulcerative blepharitis Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000000318 vitreous detachment Diseases 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention is directed to compositions that ameliorate the development of cataracts in the eye of a patient and to methods for effecting such amelioration.
- cataract development or growth is essentially halted.
- the present invention is also directed to the treatment of macular degeneration in the eye and to certain other uses.
- the compositions of this invention are capable of administration to patients without the need for injections and can be formulated into eye drops for such administration.
- Methods for treatment of cataracts and macular degeneration are also provided, as are methods for the preparation of the novel compounds and compositions useful in the practice of the invention.
- a significant retardation of the rate of cataract development in such patients may eliminate the need for many surgical cataract extractions. This reduction would provide tremendous benefits both to individual patients and to the public health system.
- a less serious but more pervasive condition of the ocular lens is presbyopia.
- the lens is enveloped by a tough collagen capsule that is thought to impart elasticity to the lens, enabling it to focus at different distances through ciliary muscle-controlled changes of curvature. As the lens ages, it increases in volume and hence progressively loses its elasticity, which diminishes an individual's ability to focus on near objects.
- presbyopia This condition is known as presbyopia, and occurs in a large percentage of the aging population.
- the eye can experience numerous diseases and other deleterious conditions that affect its ability to function normally. Many such conditions can be found in the interior and most particularly at the rear of the eye, where lies the optic nerve and the retina, seven layers of alternating cells and processes that convert a light signal into a neural signal.
- Diseases and degenerative conditions of the optic nerve and retina are the leading causes of blindness throughout the world.
- a significant degenerative condition of the retina is macular degeneration, also referred to as age-related macular degeneration (AMD). AMD is the most common cause of vision loss in the United States in those 50 or older, and its prevalence increases with age.
- AMD AMD is classified as either wet (neovascular) or dry (non-neovascular).
- the dry form of the disease is most common. It occurs when the central retina has become distorted, pigmented, or most commonly, thinned.
- the wet form ofthe disease is responsible for most severe loss of vision.
- the wet form of macular degeneration is usually associated with aging, but other diseases that can cause wet macular degeneration include severe myopia and some intraocular infections like histoplasmosis, which may be exacerbated in individuals with AIDS.
- a variety of elements may contribute to macular degeneration, including genetic makeup, age, nutrition, smoking and exposure to sunlight.
- Retinopathy associated with diabetes is a leading cause of blindness in type 1 diabetes, and is also common in type 2 diabetes.
- Diabetic retinopathy depends on the duration of the diabetes, and generally begins to occur ten or more years after onset of diabetes. Diabetic retinopathy may be classified as (1) non-proliferative or background retinopathy, characterized by increased capillary permeability, edema, hemorrhage, microaneurysms, and exudates, or 2) proliferative retinopathy, characterized by neovascularization extending from the retina to the vitreous, scarring, fibrous tissue formation, and potential for retinal detachment. Diabetic retinopathy is believed to be caused, at least in part, by the development of glycosylated proteins due to high blood glucose.
- CNNM choroidal neovascular membrane
- CME cystoid macular edema
- EEM epi-retinal membrane
- ERM molecular pucker
- CME CME
- ERM a cellophane-like membrane that forms over the macula, affecting the central vision by causing blur and distortion.
- the traction of the membrane on the macula may cause swelling.
- ERM is seen most often in people over 75 years of age. Its etiology is unknown, but may be associated with diabetic retinopathy, posterior vitreous detachment, retinal detachment or trauma, among other conditions.
- Another disease of the interior of the eye is uveitis, or inflammation of the uveal tract.
- the uveal tract is composed of the iris, ciliary body, and choroid.
- the uvea is the intermediate of the three coats of the eyeball, sandwiched between the sclera and the retina in its posterior (choroid) portion.
- Uveitis may be caused by trauma, infection or surgery, and can affect any age group. Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis affects the anterior portion of the eye, including the iris.
- Intermediate uveitis also called peripheral uveitis, is centered in the area immediately behind the iris and lens in the region of the ciliary body.
- Posterior uveitis may also constitute a form of retinitis, or it may affect the choroids or the optic nerve. Diffuse uveitis involves all parts of the eye. Glaucoma is made up of a collection of eye diseases that cause vision loss by damage to the optic nerve. Elevated intraocular pressure (IOP) due to inadequate ocular drainage is a primary cause of glaucoma. Glaucoma can develop as the eye ages, or it can occur as the result of an eye injury, inflammation, tumor or in advanced cases of cataract or diabetes. It can also be caused by certain drugs such as steroids. Further, glaucoma can develop in the absence of elevated IOP.
- IOP intraocular pressure
- This form of glaucoma has been associated with inheritance (i.e., family history of normal-tension glaucoma) Japanese ancestry, as well as systemic heart disease, such as irregular heartbeat.
- the eye produces about one teaspoon of aqueous humor daily. Normally, this fluid escapes from the eye through a spongy mesh of connective tissue called the trabecular meshwork at the same rate at which it is produced.
- Free radicals and other reactive oxygen species (ROS) cause gradual damage to the trabecular meshwork over a period of time. As a result, the trabecular meshwork becomes partially blocked, outflow facility decreases and the IOP builds up as more aqueous humor is formed.
- ROS reactive oxygen species
- Izzotti et al. provide convincing evidence linking oxidative DNA damage in a small but critical tissue structure in the outflow system to glaucoma ( Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic damage in the eyes of glaucoma patients. Am J Med. 2003; 114:638-646).
- the optic neuropathy in glaucoma include characteristic changes in the optic nerve head, a decrease in number of surviving retinal ganglion cells, and loss of vision. It has been proposed that a cascade of events links degeneration of the optic nerve head with the slow death of retinal ganglion cells observed in the disease, and that this cascade of events can be slowed or prevented through the use of neuroprotective agents (Osborne et al., 2003, Eur.
- inflammatory responses such as those resulting from allergic reaction, infection or trauma, and a variety of dystrophies (conditions in which one or more parts of the cornea lose their normal clarity due to a buildup of cloudy material), such as Fuchs' dystrophy, keratoconus, lattice dystrophy, and map-dot-fingerprint dystrophy, to name a few, as well as other disorders (e.g., dry eye syndrome).
- Ocular surface and lacrimal gland inflammation has been identified in dry eye that plays a role in the pathogenesis of ocular surface epithelial disease, termed keratoconjunctivitis sicca.
- Blepharitis is an abnormal condition wherein the tears produced contain an excess of lipids (the oily ingredient in natural tears) and, in some cases, contain an irritating oil as well. As explained hereinafter, this oil ingredient serves to prevent evaporation of the aqueous layer that wets the corneal epithelium of the eye and helps spread the aqueous layer over the normally aqueous- resistant cornea during a blink. If excess oil is present, the lipid layer will tend to adhere to the cornea itself. If the eye is unable to clear this oil from the surface of the cornea, a "dry" area occurs on the cornea since the aqueous layer is unable to hydrate this area.
- Rosacea is a disease ofthe skin (acne rosacea) and eyes (ocular rosacea) of unknown etiology and a variety of manifestations.
- the clinical and pathological features of the eye disease are nonspecific, and the disease is widely underdiagnosed by ophthalmologists.
- Retinal phototoxicity is induced by exposure of the eye to retinal illumination from an operating microscope positioned for temporal approach eye surgery or from lasers used by the military. These light sources have the potential for light-induced injury to the fovea (M. A. Pavilack and R.D. Brod "Site of Potential Operating Microscope Light-induced Phototoxicity on the Human Retina during Temporal Approach Eye Surgery" Ophthalmol. 2001, 108(2):381-385; H.F.
- Certain corneal disorders are not correctable and may be remedied only by corneal transplant, while others may be corrected by phototherapeutic keratectomy (PTK), i.e., eximer laser surgery, the process of which is also known to cause an inflammatory response, causing corneal hazing or areas of corneal opacification.
- PTK phototherapeutic keratectomy
- the skin around the eyes is also subject to disease and disorders.
- rosacea of the eyelids and blepharitis are disorders which can be severe.
- Ocular rosacea is a common and potentially blinding eye disorder with an uncertain etiology (Stone D.U. and J. Chodosh, 2004 Curr. Opin. Ophthalmol. 15(6 :499-502).
- Blepharitis of the eyes may be Staphylococcal blepharitis, seborrheic blepharitis, mixed forms of these, or the most severe form, ulcerative blepharitis.
- Oxidative stress has been implicated in the development or acceleration of numerous ocular diseases or disorders, including AMD and the various retinopathies described above (see, e.g., Ambati et al., 2003, Survey of Ophthalmology 48: 257-293; Berra et al., 2002, Arch. Gerontol. Geriatrics 34: 371-377), as well as uveitis (e.g., Zamir et al., 1999, Free Rad. Biol. Med. 27: 7-15), cataract (e.g., M.
- agents with anti-oxidative properties have been investigated as potential therapeutic agents for the treatment of such disorders.
- Many investigations have focused on the biochemical pathways that generate reducing power in cells, for example, glutathione synthesis and cycling. Enzymes, such as superoxide dismutase, that reduce activated oxygen species have also been studied to determine whether they diminish cellular oxidative stress. Compounds for inhibiting lipid oxidation in cell membranes by direct radical scavenging have also been considered to be promising therapeutic interventions.
- Nitroxides are stable free radicals that are reducible to their corresponding hydroxylamines.
- hydroxylamines are preferable to nitroxides as therapeutic agents. It has been known to provide certain hydroxylamine compositions for the prevention or retardation of cataracts.
- U.S. Patent 6,001,853 in the name of Zigler, et al., the content of which is incorporated herein by reference, reflects work performed at the National Institutes of Health of the United States. Zigler et al. identified a class of hydroxylamines which, when administered to the eye of a test animal, ameliorated cataract genesis or development.
- Compositions are also provided for the treatment of macular degeneration, various retinopathies, glaucoma, uveitis, certain disorders of the cornea, eye lid or conjuctiva, and presbyopia in the eyes of patients who exhibit or are at risk of developing such diseases or degenerative conditions.
- such compositions are formulated in topical liquid form, especially as eye drops. Periodic application of the compositions of this invention retards or halts development of cataracts or macular degeneration in treated eyes.
- the invention provides compositions, which need not be applied via injection or other uncomfortable or inconvenient routes.
- the present invention provides compositions comprising an ophthalmologically acceptable carrier or diluent and a compound having the formula:
- Ri and R 2 are, independently, H or Cj . to C 3 alkyl and R 3 and R 4 are, independently C
- R 5 is H, OH, or C ⁇ to C 6 alkyl while R 6 is CJ to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl.
- R 7 is to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or C ⁇ -C 6 cycloalkyl or heterocyclic. It is also possible for R 6 and R , or R 5 , R 6 and R , taken together, to form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.
- ophthalmic as used herein, means to have usefulness in the treatment of the eye and its diseases.
- the substituted alkyl or alkenyl species can be substituted with at least one hydroxy, alkoxy, alkylthio, alkylamino, dialkylamino, aryloxy, arylamino, benzyloxy, benzylamino or heterocyclic or YCO-Z where Y is O, N, or S and Z is alkyl, cycloalkyl or heterocyclic or aryl substituent.
- the heterocycle is a 5, 6, or 7 membered ring with at least one oxygen, sulfur, or nitrogen atom in the ring.
- R 6 and R taken together are cyclopropyl, while in others, R 6 and R 7 , taken together are tetrahydrofuranyl and R 5) R 6 and R taken together are furanyl.
- each of Ri through R 4 is Ci to C 3 alkyl, most especially ethyl or methyl, most especially, methyl.
- the compounds of the invention R 6 is Ci to C 6 alkyl substituted with at least one Ci to C 6 alkoxy or benzyloxy group.
- each of Ri through R 4 is methyl, R 5 is H or methyl, R 6 is methyl substituted with benzyloxy or Ci to C 6 alkoxy and R is methyl or where R 6 and R 7 form a cyclopropyl group.
- each of Ri through R 4 is methyl, R 5 is methyl, R 6 is ethoxy methyl and R is methyl.
- each of Ri through R is methyl, R 5 is methyl, R 6 is benzyloxy methyl and R 7 is methyl, while compounds where each of Ri through R 4 is methyl, R 5 is methyl, R 6 is hydroxymethyl and R 7 is methyl also find utility.
- compositions ofthe invention be formulated into an aqueous medium, which may be delivered in topical liquid form to the eye, via eye drops for example. Accordingly, pH and other characteristics of compositions of the invention are ophthalmologically acceptable for topical application to the eye of a patient.
- the compound is in the form of a salt, preferably a hydrochloride or similar salt.
- the compositions of the invention may contain more than one compound of the invention.
- the compositions may contain another compound known in the art for use in the treatment of a particular indication in combination with the compound(s) of the invention.
- the compounds of the invention are administered simultaneously.
- the compounds ofthe invention are administered sequentially.
- other compounds known in the art for use in the treatment of the diseases and disorders described herein may be administered with the compound(s) of the invention either simultaneously or sequentially.
- the invention also provides methods of treatment of diseases and disorders using such combination therapy.
- the compositions preferably further comprise an anti-oxidant agent, especially a sulfhydryl compound.
- an anti-oxidant agent especially a sulfhydryl compound.
- exemplary compounds include mercaptopropionyl glycine, N-acetylcysteine, ⁇ - mercaptoethylamine, glutathione and similar species, although other anti-oxidant agents suitable for ocular administration, e.g. ascorbic acid and its salts or sulfite or sodium metabisulfite may also be employed.
- the amount of hydroxylamines may range from about 0.1% weight by volume to about 10.0%; weight by volume and preferred is about 0.25%- weight by volume to about 10.0% weight by volume.
- the invention can also be seen to provide ophthalmologic compositions comprising an ophthalmologically acceptable carrier or diluent together with a compound having an N- hydroxypiperidine portion bound to a solubility modifying portion.
- the active moiety, hydroxylamine can be delivered to the lens of an eye in need of treatment in a "stealth" form, that is, in the form of a chemical compound that can have the hydroxylamine portion cleaved from the balance of the molecule.
- the compound is broken down in the eye to give rise to the active hydroxylamine species for effective treatment of cataracts, macular degeneration or any of the other eye disorders referred to herein.
- the compound thus provided has a solubility in water at 25 °C of at least about 0.1% by weight and a water - n- octanol partition coefficient at 25 °C of at least about 3.
- the water solubility is greater than about 0.5% by weight, preferably greater than about 2.0% and the partition coefficient is greater than about 5, preferably greater than about 10. Accordingly, it is desired that the compounds used be such that, upon administration topically to the eye, they penetrate the cornea and are converted to the desired hydroxylamine, preferably, an N-hydroxypiperidine.
- the hydroxylamine portion comprises -l,4-dihydroxy-2,2,6,6-tetramethylpiperidine.
- the invention includes methods for ameliorating - either slowing or arresting entirely - the development of a cataract in the lens of a patient.
- the invention includes methods for ameliorating the development of, or otherwise treating, presbyopia, macular degeneration, various retinopathies, glaucoma, uveitis, corneal disorders (particularly those associated with trauma, inflammation (both of which can be caused by eximer laser surgery), aging, UV exposure and other oxidative-related disorders), disorders of the conjunctiva (conjunctivitis), dry eye syndrome, blepharitis and rosacea of the eye.
- the invention also provides methods for protecting retinal pigment epithelium against photooxidative damage.
- the methods comprise administering to the eye an ophthalmologic composition comprising an ophthalmologically acceptable carrier or diluent in the form of eye drops containing a compound having one or more ofthe foregoing compounds as an active ingredient therein. It is preferred that the administration takes place a plurality of time and, in certain preferred embodiments, chronic, periodic administration is performed.
- ophthalmic compositions of the invention are used as a prophylactic treatment to prevent or delay development of certain age-related ocular conditions, including cataracts, presbyopia, corneal degeneration and dystrophy, glaucoma, macular degeneration and photooxidative retinal damage.
- the compositions are formulated as eyedrops or eye washes.
- the invention also provides methods for identifying pharmaceuticals that can be delivered to the lens of a patient in the form of eye drops. These methods comprise selecting a compound having a water solubility at 25°C of at least about 0.1% by weight and a water/n- octanol partition coefficient of at least about 5 at 25 °C, which compound is enzymatically cleavable under conditions obtaining in the eye of a patient to give rise to a proximate drug for treatment of a condition of the eye, preferably the lens.
- the active pharmaceutical species is a hydroxylamine, especially one having an N-hydroxypiperidine nucleus.
- Figure 1 depicts aqueous humor levels of tempol-H (1,4-dihydroxy- 2,2,6,6- tetramethylpiperidine) in rabbit eyes treated topically with Compound 1 of the invention or with tempol-H.
- Figure 2 depicts levels of tempol-H in various tissues of rabbit eyes following topical administration of Compound 1, at selected time points post-treatment.
- Figure 3 shows that various concentrations of tempol-H protect blue light-illuminated A2E-laden RPE cells.
- Figure 4 shows the effect of 1 mM tempol-H in protection of blue light-illuminated A2E-laden RPE cells.
- the present invention provides compounds and compositions that can be administered topically to the eyes of patients who exhibit, or who are developing or are at risk of developing cataracts, presbyopia, uveitis, macular degeneration or other retinopathies, including but not limited to diabetic retinopathy, choroidal neovascular membrane (CNVM), cystoid macular edema (CME), epi-retinal membrane (ERM) (macular pucker) and macular hole, as well as disorders of the cornea (and surrounding eye lids and conjuctiva), including but not limited to inflammation, trauma, irradiation damage, corneal neovascularization and various dystrophies such as Fuch's dystrophy, keratoconus, lattice dystrophy and map-dot- fingerprint dystrophy, as well as dry eye syndrome, blepharitis and rosacea of the eye.
- CNVM choroidal neovascular membrane
- CME cystoid macular edema
- the present invention should be viewed as "pioneering" and as having satisfied a long - felt, but unserved need in the art.
- the inventors have demonstrated that the compounds of the present invention are absorbed into and across the cornea and sclera, through the uvea and into the lens and interior of the eye. Enzymatic processes within these tissues cleave the N-hydroxypiperidine portion of the compound from the acid to which it was esterified. The N-hydroxypiperidine moiety, once liberated, then performs the same functions with the same efficacy as demonstrated by Zigler.
- a further advantage ofthe compounds of he invention is that, even in their esterified form, they have been found to possess free radical-scavenging and antioxidant activities as seen in tempol-H and other non-esterified hydroxylamine compounds.
- the compounds of the invention have not been known heretofore for administration to the eye. They have certainly not been known for use in the treatment of cataract, presbyopia, corneal disorders, macular degeneration, retinopathies, glaucoma or uveitis.
- compositions comprising a pharmaceutically carrier or diluent and a compound having the formula:
- Ri and R 2 are, independently, H or Ci to C 3 alkyl; R 3 and R 4 are, independently Ci to C 3 alkyl; and where Ri and R 2 , taken together, or R 3 and R , taken together, or both may be cycloalkyl;
- R 5 is H, OH, or Ci to C 6 alkyl;
- R 6 is Ct to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl;
- R 7 is Ci to C 6 alkyl, alkenyl, alkynyl, substituted alkyl, alkenyl, cycloalkyl, or heterocycle or where R 6 and R , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.
- the present invention provides an ophthalmically acceptable carrier or diluent and a compound having an N-hydroxy piperidine portion bound to a solubility modifying portion, the compound having a solubility in water at 25 °C of at least about 0.25% by weight and a water - n-octonal partition coefficient at 25°C of at least about 5.
- the composition may have the N-hydroxy piperidine portion cleavable from the compound under conditions found in the eye. It is foreseeable that this portion is cleaved under conditions in the lens of the eye.
- the N-hydroxy piperidine portion may be cleaved enzymatically.
- compositions may also exist wherein the N-hydroxy piperidine portion is l-oxyl-4-hydroxy- 2,2,6,6-tetramethylpiperidyl.
- Ci to C n alkyl, alkenyl, or alkynyl in the sense of this invention, means a hydrocarbyl group having from 1 to n carbon atoms in it. The term thus comprehends methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and the various isomeric forms of pentyl, hexyl, and the like.
- the term includes ethenyl, ethynyl, propenyl, propynyl, and similar branched and unbranched unsaturated hydrocarbon groups of up to n carbon atoms.
- groups may be functionalized such as with one or more hydroxy, alkoxy, alkylthio, alkylamino, dialkylamino, aryloxy, arylamino, benzyloxy, benzylamino, heterocycle, or YCO-Z, where Y is O, N, or S and Z is alkyl, cycloalkyl, heterocycle, or aryl substituent.
- carbocycle defines cyclic structures or rings, wherein all atoms forming the ring are carbon. Exemplary of these are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. Cyclopropyl is one preferred species.
- Heterocycle defines a cyclic structure where at least one atom of the ring is not carbon. Examples of this broad class include furan, dihydrofuran, tetrahydrofuran, pyran, oxazole, oxazoline, oxazolidine, imidazole and others, especially those with an oxygen atom in the ring.
- each of Ri through R 4 be lower alkyl that is d to C 3 alkyl.
- all these groups are methyl for convenience in synthesis and due to the known efficacy of moieties having such substitution at these positions.
- substituents may be used as well.
- compounds are employed where R 6 is Ci to C 6 alkyl substituted with at least one Ci to C 6 alkoxy or benzyloxy group. Preferred among these are compounds having ethoxy or benzyloxy substituents.
- each of Ri through R is methyl, R 5 is H or methyl, R 6 is methyl substituted with benzyloxy or Ci to C 6 alkoxy, and R is methyl or where R 6 and R 7 form a cyclopropyl group as well as the compound in which each of Ri through R 4 is methyl, R 5 is methyl, R 6 is ethoxy or benzyloxy methyl, and R is methyl.
- An additional preferred compound is one in which each of Ri through R 4 is methyl, R 5 is methyl, R 6 is hydroxymethyl, and R 7 is methyl.
- compositions for application to the eye of patients in need of therapy are adapted for pharmaceutical use as an eye drop or in contact lenses, inserts or the like, as described in greater detail below.
- compositions of the invention may also have antioxidants in ranges that vary depending on the kind of antioxidant used. The usage also depends on the amount of antioxidant needed to allow at least 2 years shelf-life for the pharmaceutical composition. One or more antioxidants may be included in the formulation. Certain commonly used antioxidants have maximum levels allowed by regulatory authorities.
- the amount of antioxidant(s) to be administered should be enough to be effective while not causing any untoward effect.
- Such doses may be adjusted by a physician as needed, within the maximum levels set by regulatory authorities, and is well within the purview of the skilled artisan to determine the proper and effective dose.
- Reasonable ranges are about 0.01% to about 0.15% weight by volume of EDTA, about 0.01% to about 2.0% weight volume of sodium sulfite, and about 0.01% to about 2.0% weight by volume of sodium metabisulfite.
- N- Acetylcysteine may be present in a range of about 0.1% to about 5.0% weight by volume, with about 0.1% to about 10% of hydroxylamine concentration being preferred. Ascorbic acid or salt may also be present in a range of about 0.1% to about 5.0% weight by volume with about 0.1% to about 10% weight by volume of hydroxylamine concentration preferred.
- Other sulfhydryls, if included, may be the same range as for N-acetylcysteine.
- Other exemplary compounds include mercaptopropionyl glycine, N-acetyl cysteine, ⁇ - mercaptoethylamine, glutathione and similar species, although other anti-oxidant agents suitable for ocular administration, e.g.
- a buffering agent may be used to maintain the pH of eye drop formulations in the range of about 4.0 to about 8.0; this is necessary to prevent corneal irritation. Because the compounds of this invention are esters, the pH is preferably maintained at about 3.5 to about 6.0, preferably about 4.0 to about 5.5, in order to prevent hydrolysis of the ester bond and to ensure at least a 2-year shelf life, for the product. This pH also ensures that most of the hydroxylamine is in its protonated form for highest aqueous solubility.
- the buffer may be any weak acid and its conjugate base with a pKa of about 4.0 to about 5.5; e.g.
- acetic acid/sodium acetate citric acid/sodium citrate.
- the pKa of the hydroxylamines is about 6.0.
- formulations should be at pH 7.2 to 7.5, preferably at pH 7.3-7.4.
- the compounds of the present invention may also include tonicity agents suitable for administration to the eye. Among those suitable is sodium chloride to make formulations of the present invention approximately isotonic with 0.9% saline solution.
- the compounds of the invention are formulated with viscosity enhancing agents. Exemplary agents are hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and polyvinylpyrrolidone.
- the viscosity agents may exists in the compounds up to about 2.0% weight by volume. It may be preferred that the agents are present in a range from about 0.2% to about 0.5% weight by volume. A preferred range for polyvinylpyrrolidone may be from about 0.1% to about 2.0% eight by volume. One skilled in the art may prefer any range established as acceptable by the Food and Drug Administration.
- the compounds of the invention may have co-solvents added if needed. Suitable cosolvents may include glycerin, polyethylene glycol (PEG), polysorbate, propylene glycol, mannitol and polyvinyl alcohol. The presence of the co-solvents may exist in a range of about 0.2% to about 4.0% weight by volume.
- mannitol may be formulated in the compounds of the invention in a range of about 0.5% to about 4.0% weight by volume. It may also be preferred that polyvinyl alcohol may be formulated in the compounds of the invention in a range of about 0.1% to about 4.0% weight by volume.
- mannitol may be formulated in the compounds of the invention in a range of about 0.5% to about 4.0% weight by volume.
- polyvinyl alcohol may be formulated in the compounds of the invention in a range of about 0.1% to about 4.0% weight by volume.
- One skilled in the art may prefer ranges established as acceptable by the Food and Drug Administration. Preservatives may be used in the invention within particular ranges.
- Formulations for injection are preferably designed for single-use administration and do not contain preservatives. Injectable solutions should have isotonicity equivalent to 0.9% sodium chloride solution (osmolality of 290-300 mOsmoles).
- compositions of the invention may contain more than one compound of the invention.
- the compositions of the invention contain at least one compound of the invention.
- the compounds of the invention are administered simultaneously.
- the compounds of the invention are administered sequentially.
- the methods of the invention include combination therapy.
- the compound(s) of the invention are administered with another compound known in the art that is useful for treating a disease or disorder that is the target of the compounds of the invention.
- the composition of the invention may further contain at least one other compound known in the art for treating the disease or disorder to be treated.
- the other compound(s) known in the art may be administered simultaneously with the compound(s) of the invention, or may be administered sequentially.
- the methods of the invention include using such combination therapy.
- the tissues, including the lens, of the anterior chamber of the eye are bathed by the aqueous humor. This fluid is in a highly reducing redox state because it contains antioxidant compounds and enzymes.
- the lens is also a highly reducing environment, which maintains the hydroxlamine compounds in the preferred reduced form. Therefore, it may be advantageous to include a reducing agent in the eye drop formulation, or to dose separately with a reducing agent to maintain the hydroxylamine in its reduced form.
- Preferred reducing agents may be N-acetylcysteine, ascorbic acid or a salt form, and sodium sulfite or metabisulfite, with ascorbic acid and/or N-acetylcysteine or glutathione being particularly suitable for injectable solutions.
- a combination of N-acetylcysteine and sodium ascorbate may be used in various formulations.
- a metal chelator antioxidant such as EDTA (ethylenediaminetetraacetic acid) or possibly DTPA (diethylenetriaminepentaacetic acid) may also be added to keep the hydroxylamine in the reduced form in the eye drop formulation.
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- the compounds of the invention exert their anti-caractogenic and other therapeutic effects in two ways.
- the ester compounds are hydrolyzed in situ to form hydroxylamine components that exert therapeutic activity.
- the esterified compounds themselves possess anti-caractogenic and antioxidant activity, thereby supporting the therapeutic efficacy of pharmaceutical preparations comprising the compounds.
- esterases are known to be present in ocular tissues, especially the cornea.
- the specific esterase(s) that cleaves the esters of the present series need not be identified in order to practice the invention.
- the cleavage of the esters occurs rapidly and essentially completely on administering the compounds to the eyes of rabbits. This is shown by the presence of tempol-H in the aqueous humor at all times (30, 60, 90 and 120 minutes) examined after topical dosing.
- the esters are stable in aqueous solutions; e.g.
- the present invention has optimal use in ameliorating the development of a cataract in the eye of a patient.
- Another optimal use includes the treatment of macular degeneration in the retina of a patient.
- Yet other optimal uses include treatment, reduction or prevention of the development of diabetic retinopathy and various other retinopathies as described herein, as well as the treatment of uveitis and glaucoma.
- Still another optimal use is the treatment of corneal disorders, particularly those associated with oxidative stress, such as inflammation or trauma (which can be, but are not necessarily, associated with surgery) and various dystrophies.
- the compounds and compositions of the invention may also be used to reduce, prevent or ameliorate photooxidative damage to retinal pigment epithelium, and for amelioration of irritation and inflammation during laser surgery of the eye, including trabeculectomy treatment for glaucoma and keratectomy for corneal reshaping.
- the compounds and compositions may also be used to treat diseases and disorders of the conjunctiva and eyelids. Further, the compounds and compositions ofthe invention may be used to treat alopecia and damage to rectal tissue following radiation therapy. Many of the disorders and conditions described herein, particularly cataract, presbyopia and macular degeneration, are progressive conditions of the aging process.
- compositions of the invention may be used to advantage as a prophylactic treatment to prevent or delay development of these age-related ocular conditions.
- the compositions are formulated as eyedrops or eye washes. They are administered to the eye prior to, or at the initial stages of, development of age-related conditions of the eye.
- Compositions comprising the compounds of the invention may be delivered to the eye of a patient in one or more of several delivery modes known in the art.
- the compositions are topically delivered to the eye in eye drops or washes.
- compositions are delivered in a topical ophthalmic ointment, which is particularly useful for treating conditions of the cornea, conjuctiva or surrounding skin, such as dry-eye and blepharitis.
- the compositions may be delivered to various locations within the eye via periodic subconjunctival or intraocular injection, or by infusion in an irrigating solution such as BSS® or BSS PLUS® (Alcon USA, Fort Worth, TX) or by using pre-formulated solutions of the hydroxylamines in compositions such as BSS® or BSS PLUS®.
- the use of the compounds of the invention in vitrectomy may be effective in reducing or preventing the development of vitrectomy- associated cataracts.
- compositions may be applied in other ophthalmologic dosage forms known to those skilled in the art, such as pre-formed or in situ-i rmed gels or liposomes, for example as disclosed in U.S. Patent 5,718,922 to Herrero-Vanrell.
- ophthalmologic dosage forms known to those skilled in the art, such as pre-formed or in situ-i rmed gels or liposomes, for example as disclosed in U.S. Patent 5,718,922 to Herrero-Vanrell.
- a direct injection of drugs into the vitreous body used for treating diseases has been used, in which microspheres or liposomes were used to release drugs slowly (Moritera, T. et al. "Microspheres of biodegradable polymers as a drug-delivery system in the vitreous" Invest. Ophthalmol. Vis. Sci. 1991 32(6): 1785-90).
- the composition may be delivered to or through the lens of an eye in need of treatment via a contact lens (e.g. Lidofilcon B, Bausch & Lomb CW79 or DELTACON (Deltafilcon A) or other object temporarily resident upon the surface of the eye.
- a contact lens e.g. Lidofilcon B, Bausch & Lomb CW79 or DELTACON (Deltafilcon A) or other object temporarily resident upon the surface of the eye.
- a contact lens e.g. Lidofilcon B, Bausch & Lomb CW79 or DELTACON (Deltafilcon A) or other object temporarily resident upon the surface of the eye.
- a contact lens e.g. Lidofilcon B, Bausch & Lomb CW79 or DELTACON (Deltafilcon A) or other object temporarily resident upon the surface of the eye.
- a contact lens e.g. Lidofilcon B, Bausch & Lomb CW
- compositions can also be administered by infusion into the eyeball, either through a cannula from an osmotic pump (ALZET®, Alza Corp., Palo Alto, Calif.) or by implantation of timed- release capsules (OCCUSENT®) or biodegradable disks (OCULEX®, OCUSERT®) which contain the compositions.
- AZAT® osmotic pump
- OCUSENT® timed- release capsules
- OCULEX®, OCUSERT® biodegradable disks
- a preferred method to treat dry eye symptoms utilizes aqueous based solutions or gels, which may be formulated to contain one or more compounds of the present invention.
- the "active" ingredients in these artificial tear formulations are common water soluble or dispersable polymers such as hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycol, carbomers and poloxamers.
- U.S. Patent 6,429,194 describes aqueous ophthalmic preparations for instillation into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac.
- the ophthalmic preparation includes a mucin component, similar to that found at the normal human ocular surface.
- patent No. 6,281,192 also describes the ophthalmic applications of mucin.
- An ophthalmic solution must provide an effective and long lasting treatment for symptoms of dry eye.
- One approach to achieving these aims is to provide a solution with tailored rheological properties, that is, a high viscosity solution that yields or flows under stress. Examples of this approach are disclosed in U.S. Pat. Nos. 5,075,104 and 5,209,927, where the rheological properties of the ophthalmic solutions are attained through the use of carbomer polymers. These carbomer polymers have been found to be bio-adhesive as described in U.S. Pat. Nos. 5,225,196; 5,188,828; 4,983,392 and 4,615,697.
- the method comprises applying an admixture of a charged phospholipid and a non-polar oil over the eye, preferably in the form of a finely divided oil- in-water emulsion.
- a charged phospholipid and a non-polar oil preferably in the form of a finely divided oil- in-water emulsion.
- liposome compositions in the form of emulsions are reported to enhance retention on ocular surfaces and thereby alleviate the symptoms of dry eye.
- Several other types of delivery systems are available that are particularly suitable for delivering pharmaceutical compositions to the interior or posterior of the eye.
- U.S. Patent 6,154,671 to Parel et al. discloses a device for transferring a medicament into the eyeball by iontophoresis.
- the device utilizes a reservoir for holding the active agent, which contains at least one active surface electrode facing the eye tissue lying at the periphery of the cornea.
- the reservoir also has a return electrode in contact with the patient's partly closed eyelids.
- U.S. Patent 5,869,079 to Wong et al. discloses combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release ocular implant.
- U.S. Patent 6,375,972 to Guo et al. U.S. Patent 5,902,598 to Chen et al.
- U.S. Patent 6,331,313 to Wong et al U.S. Patent 5,707,643 to Ogura et al.
- Patent 5,466,233 to Weiner et al. and U.S. Patent 6,251,090 to Avery et al. each describes intraocular implant devices and systems that may be used to deliver pharmaceutical compositions comprising compounds of the present invention.
- U.S. Pat. No. 4,014,335 describes an ocular drug delivery device placed in the cul-de- sac between the sclera and lower eyelid for administering the drug and acting as a reservoir.
- the device comprises a three-layered laminate of polymeric materials holding the drug in a central reservoir region of the laminate.
- the drug diffuses from the reservoir through at least one of the polymeric layers of the laminate.
- Solid devices, in the form of ocular inserts, have been utilized for longer term symptomatic relief of dry eye.
- compositions of the present invention may include oral tablets, liquids and sprays; intravenous, subcutaneous and intraperitoneal injections; application to the skin as a patch or ointment; enemas, suppositories, or aerosols.
- oral tablets, liquids and sprays may include oral tablets, liquids and sprays; intravenous, subcutaneous and intraperitoneal injections; application to the skin as a patch or ointment; enemas, suppositories, or aerosols.
- the dosing may occur less frequently if the compositions are formulated in sustained delivery vehicles, or are delivered via implant. For topical delivery, it may be preferred that dosing occur one to four times daily for as long as needed.
- the dosage amount may be one or two drops per dose.
- the dosage schedule may also vary depending on the active drug concentration, which may depend on the hydroxylamine used and on the needs of the patient. It may be preferred that the active amount be from about 0.1% to about 10.0% weight by volume in the formulation. In some embodiments, it is preferable that the active drug concentration be 0.25% to about 10.0% weight by volume.
- the concentration of the hydroxylamine component will preferably be in the range of about 0.1 ⁇ M to about 10 mM in the tissues and fluids.
- the range is from 1 ⁇ m to 5 mM, in other embodiments the range is about 10 ⁇ M to 2.5 mM. In other embodiments, the range is about 50 ⁇ M to 1 mM.
- Most preferably the range of hydroxylamine concentration will be from 1 to 100 ⁇ M.
- the concentration of the reducing agent will be from 1 ⁇ M to 5 mM in the tissues or fluids, preferably in the range of 10 ⁇ M to 2 mM.
- the concentrations of the components of the composition are adjusted appropriately to the route of administration, by typical pharmacokinetic and dilution calculations, to achieve such local concentrations. Alternatively, penetration of cornea and absorption into other tissues in the interior of the eye is demonstrated using radiolabeled hydroxylamine.
- an ophthalmologist or one similarly skilled in the art will have a variety of means to monitor the effectiveness of the dosage scheme and adjust dosages accordingly.
- effectiveness in treating cataract may be determined by the ophthalmologist by observing the degree of opacity of the lens at intervals by slit-lamp examination, or other means known in the art.
- Effectiveness in the treatment of macular degeneration or other retinopathies may be determined by improvement of visual acuity and evaluation for abnormalities and grading of stereoscopic color fundus photographs. (Age-Related Eye Disease Study Research Group, NEI, NIH, AREDS Report No. 8, 2001, Arch. Ophthalmol. 119: 1417-1436).
- Effectiveness in the treatment of uveitis may be dete ⁇ nined by improvement in visual acuity and vitreous haze and control of inflammation (Foster et al., 2003, Arch. Ophthalmol. 121: 437-40). Following such evaluation, the ophthalmologist may adjust the frequency and/or concentration of the dose, if needed.
- Another aspect of the invention features a method of identifying a pharmaceutical for delivery to the eye of a patient in the form of eye drops, which comprises selecting a compound having a water solubility at 25 °C of at least about 0.25% by weight and a water - n-octonal partition coefficient of at least about 5 at 25°C, which compound is enzymatically cleavable under conditions obtained in the lens of the eye of a patient to give rise to a hydroxylamine, preferably an N-hydroxy piperidine.
- the selected compound is an ester of the hydroxylamine. It may be preferred that at least 0.1% solubility is needed for an eye drop, even for a suspension formulation. Completely water-insoluble compounds may not be effective.
- Esters that are soluble in water are preferred. Esters with less than 0.1% solubility may be used in the form of suspensions or ointments or other formulations. Solubility is determined by mixing lOOmg of test compound with 1 ml of water, at room temperature and adding additional 1 ml quantities of water, with mixing, until ester dissolves completely. Corneal penetration is shown by measuring a substantial concentration (e.g. >5 ⁇ M) of the effective hydroxylamine and/or ester in the aqueous humor after administering a solution of the compound in vivo to the eyes of rabbits.
- a substantial concentration e.g. >5 ⁇ M
- ESR electron spin resonance
- HPLC high performance liquid chromatography
- GC gas chromatography
- Penetration of compounds to the interior or posterior of the eye is likewise shown by measuring the concentration of the compound in the vitreous humor, uvea or retina after administering a solution of the compound to the eyes of rabbits.
- Esters are selected for these tests based on their calculated or measured octanol/water partition coefficient (P).
- Hydrophilic compounds such as tempol-H cannot penetrate the lipophilic epithelial layer of the cornea.
- Partition coefficients of tempol-H and esters that penetrate are as follows: P (Calculated)* Tempol-H 0.8 (measured, 0.5) Ester 4 16.4 Ester 8 8.2 Ester 14 6.3 * Clog P version 4.0, Biobyte Corporation Enzymatic conversion is essentially complete at greater than 90% hydrolysis of the ester in vivo to the alcohol and acid after administering the compound to the eye of rabbits.
- the conversion may be determined by HPLC or GC assay of a selected eye tissue (e.g., aqueous humor).
- the enzymatic conversion may be determined by incubating the compound in plasma or eye tissue homogenate and assaying samples periodically by HPLC or GC to monitor the rate of breakdown.
- Esters with a half-life of less than about 1 or 2 hours are preferred candidates. This method may be the preferred screening procedure before in vivo testing. Esters should have less than about 10% hydrolysis at 40°C, after 3 months, in aqueous solution at pH 4.0-5.0. This extrapolates to a shelf life of the ester in solution of at least 18 months at room temperature, which may be preferred for an eye drop product.
- Example 1 Determination of Ester Compound Stability In Aqueous Solution.
- a 0.1-0.5% solution of the ester compound was prepared in buffer (pH 4.5-5.0) containing DTPA or EDTA. The solution was filled into amber glass vials, which were sealed and placed in a controlled temperature container maintained at 40°C. Sample vials were removed periodically and stored at 0-5°C until analyzed by HPLC, GC, or GC/MS analytical methods, and found to be stable after 3 months under these conditions.
- the agent To be useful as an anti-cataract drug the agent must penetrate into the lens. This may be included in the method for selecting an anti-cataract compound.
- a description of method for tempol-H follows:
- Example 2 Drug Penetration of Organ Cultured Rat Lenses
- tempol-H and tempol have a remarkable ability to penetrate lens tissue from the surrounding fluid.
- the experiments described in this section determined the time course, active compound concentrations and compound distribution in the lens, after incubation with rat lenses under the organ culture conditions.
- Rat lenses were cultured as follows: Rat lenses were obtained from Sprague- Dawley rats. The lenses were incubated in 24- ell cluster dishes in modified TC-199 medium and were placed in a 37°C incubator with a 95% air/5% CO 2 atmosphere. The lenses were incubated in 2 ml of culture medium, which was adjusted to 300 milliosmoles ( Osm).
- Lenses were incubated, for 1 to 24 hours, in the culture medium with 4.0 mM tempol-H, or with 4.0 mM of the oxidized form, tempol. At the appropriate time, the lenses were removed from the medium, blotted dry, homogenized and were analyzed for active compound by electron spin resonance method (ESR). In one experiment, lenses were incubated for 4 hours and dissected into epithelial, cortical and nuclear sections before analysis. Results: Concentrations (mM, in lens water) of tempol-H reached 0.4 mM, 0.8 mM and 1.0 mM, respectively, after 1, 2 and 4 hours incubation of active compound.
- ESR electron spin resonance method
- Example 3 l-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6- tetramethylpiperidine l'-carbonyldiimidazole was added in small portion (1.27 g, 7.84 mmol) to a stirred solution of 3-etho ⁇ y-2,2-dimethylpropionic acid (750 mg, 7.13 mmol; prepared according to the procedure described in J. Org. Chem., 38, 2349, 1975, the content of which was incorporated herein by reference) in dry DMF (10 mL). A vigorous gas evolution was observed. This solution was heated at 100°C for 1 h.
- Example 2 The nitroxide of Example 2 (1.02 mg, 3.34 mmol) was added to a solution of saturated hydrogen chloride in ethanol (20 mL). The red color disappears quickly and the resulting yellow colored solution was boiled to give a clear colorless solution. The solution was concentrated in vacuo, "was dissolved in 100 mL ethyl acetate and was washed with saturated NaHCO 3 to obtain the hydroxylamine free-base. The ethyl acetate layer was separated and concentrated to give a red colored oil which was mostly nitroxide, by TLC.
- This oil was purified by column chromatography on silica gel using cyclohexane:ethyl acetate (4:1) as eluent to give a red colored crystalline solid (700 mg).
- the solid was dissolved in a solution of saturated hydrogen chloride in ethanol (20 mL), was concentrated in v ⁇ cuo, and was recrystallized from ethyl acetate :diisopropylether (2:1, 50 mL) to give white crystalline solid (320 mg). m. ⁇ .l40-142°C (dec).
- Example 5a 1 -oxyl-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpi ⁇ eridine
- Example 5b Alternative method - l-oxyl-4-cyclopropanecarbonyloxy-2,2,6,6- tetramethylpiperidine l,l'-Carbonyldiimidazole (1.78 g, 11 mmol) was added in small portions to a stirred solution of cyclopropanecarboxylic acid (860 mg, 10 mmol) in dry DMF (10 mL). A vigorous gas evolution was observed. This solution was heated at 40°C for 1 h.
- Example 5c Alternative method - l-oxyl-4-cyclopropanecarbonyloxy-
- Example 5a The nitroxide of Example 5a (2.2g, 9.15 mmol) was added to a solution of saturated hydrogen chloride in ethanol (20 mL). The red color disappeared quickly and the resulting yellow colored solution was boiled to give clear colorless solution. The solution was concentrated in vacuo, dissolved in 100 mL ethyl acetate and was washed with saturated NaHCO 3 to obtain the hydroxylamine free-base. The ethyl acetate layer was separated, acidified with ethereal HCl, and concentrated to give white solid, which was recrystallized from ethanol (10 mL) as a white crystalline solid 1.15g (4.13 mmol, 45.1 %). m.p. 224-228°C (dec).
- Example 5a The nitroxide of Example 5a (700 mg, 2.91 mmol) was added to a solution of saturated hydrogen chloride in ethanol (20 mL). The red color disappeared quickly and the resulting yellow colored solution was boiled to give a clear colorless solution. The solution was concentrated in vacuo, dissolved in 100 mL ethyl acetate and concentrated to half volume to give a white crystalline solid, 627 mg (2.25 mmol, 77.5 %.). m.p.224-227°C (dec).
- Example 8 l-oxyl-4-(3 '-benzyloxy-2',2'-dimethyl) ⁇ ropanecarbonyloxy-2,2,6,6- tetramethylpiperidine
- Example 8 The nitroxide of Example 8 (1.02 mg, 3.34 mmol) was added to a solution of saturated hydrogen chloride in ethanol (20 mL). The red color disappears quickly and the resulting yellow colored solution was boiled to give clear colorless solution. The solution was concentrated in vacuo and the residue dissolved in ethyl acetate (20 mL). Hexane (20 mL) was added and product began to oil out; the mixture was then allowed to stand for 12 h. An oily residue was obtained by decantation ofthe solvent and it was treated with was isopropyl ether and warmed.
- Example 12 l-hydroxy-4-(l-methyl-cyclopropane)carbonyloxy-2,2,6,6- tetramethylpiperidine hydrochloride
- the nitroxide of Example 11 (700 mg, 2.91 mmol) was added to a solution of saturated hydrogen chloride in ethanol (10 mL). The red color disappears quickly and the resulting yellow colored solution was boiled to give a clear colorless solution. The solution was concentrated in vacuo to give white crystalline solid, which was filtered, washed with ethyl acetate and dried in vacuo (0.700 mg, 2.4mmol, 82.7%) m.p. 215°C -220°C (dec).
- Example 13 The nitroxide of Example 13 (300 mg, 1.13mmol) was added to a solution of saturated hydrogen chloride in ethanol (10 mL). The red color disappeared quickly and the resulting yellow colored solution was boiled to give clear colorless solution. The solution was kept at room temperature for 1 h and a white crystalline solid separated. It was filtered, washed with ethyl acetate and dried in vacuo to afford the hydroxylamine (220 mg, 0.72mmol, 64.5%, m.p. 209.4°C -210.4°C). 1H-NMR (270 MHz, D 2 O) ppm: 1.49 (6H ?
- Example 15 The nitroxide of Example 15 (300 mg, 1.11 mmol) was added to a solution of saturated hydrogen chloride in ethanol (10 mL). The red color disappeared quickly and the resulting yellow colored solution was boiled to give a clear colorless solution. The solution was kept at room temperature for 1 h and a white crystalline solid separated. The solid was filtered, washed with ethanol and dried in vacuo to afford product (146 mg, 0.48 mmol, 42.86%, m.p. 221.0°C-223.2°C).
- Compound 3 R Groups of six New Zealand White rabbits were used in the study to evaluate the absorption of tempol-H and compound 1.
- the test compounds were prepared in sterile saline solutions at a concentration of 3.5% weight by volume.
- the animals were held in restraining boxes during instillation of eye drops, 50 ⁇ L in each eye, using a micropipette. After dosing, the eye was gently held closed for 60 seconds.
- the rabbits were dosed twice daily for 4 consecutive days. On the fifth day, rabbits were dosed once and then euthanized at 30 minutes post dose (2 rabbits), 60 minutes post-dose (2 rabbits) and at 120 minutes post-dose (2 rabbits). Immediately after euthanization, aqueous humor was collected from each rabbit.
- aqueous concentration of tempol-H in each sample was measured using the electron spin resonance (ESR) method.
- ESR electron spin resonance
- Aqueous humor concentrations of tempol-H after dosing with compound 1 were maximal at 3O minutes post- dose but were still present at 2 hours post-dose, (see Figure 1 and Table 1).
- Example 18 Identification of Metabolites of Compound 1 in Rabbit Eye Aqueous humor samples, from the in vivo rabbit study described in Example 16 were identified by GC/MS for the presence of compound 1 and its metabolites, tempol-H and carboxylic acid (RiCOOH), formed by hydrolysis of compound 1 by ocular esterases. Both the metabolites were observed but not Compound 1. This confirmed that Compound 1 was completely converted to its metabolites.
- a sample of aqueous humor was freeze dried in a lOmL amber colored glass vial containing a tiny magnetic bar. To this was added lmL of methylene chloride and the solution was stirred for two minutes and allowed to stand for five minutes.
- Example 19 Tolerance of compound 1 in vivo in Rabbit Eyes Eyedrops containing 3.5 % compound 1 were administered six times, at 1-hour intervals, to each eye of two conscious rabbits. The drug was well tolerated and no adverse findings were noted in this preliminary study.
- Example 20 Ocular Bioavailability in Rabbit The ocular bioavailability of compounds 2 and 3 was evaluated in New Zealand White rabbits. Each compound was dissolved in lOmM phosphate buffer, pH 7.0 to a concentration of 125mM. This concentration was equal to ⁇ 3.5% for compounds 2 and 3. Fifty ⁇ l was instilled onto the cornea of both eyes of each rabbit 6 times at 1-hour intervals. Two rabbits were used for each compound.
- One rabbit treated with each compound was euthanized 30 minutes after the last dose and the second was euthanized 90 minutes after the final dose. After death, the eyes of each rabbit were immediately enucleated and a blood sample was collected from the orbit. Aqueous humor was collected from each eye with a syringe and then the lens was dissected from the eye. The capsule/epithelium was carefully separated from the fiber mass and both parts were frozen on dry ice, the capsule/epithelium in lOO ⁇ l of 5 mM DTPA (diethylenetriaminepentaacetic acid) solution and the fiber mass in a sealed vial without added liquid. Likewise, the aqueous and blood samples were quick frozen.
- 5 mM DTPA diethylenetriaminepentaacetic acid
- each eye including the cornea, retina, sclera and vitreous were frozen for possible future dissection and analysis. All samples were transported to the lab on dry ice and were stored at -75°C until processed. The aqueous concentration of tempol-H in each sample was measured using the electron spin resonance (ESR) method. Analysis of the aqueous humor reveals that both compounds penetrated the cornea and entered the aqueous chamber. The highest concentrations for both compounds was present in the 30-minute sample with the 90-rninute samples being significantly reduced in concentration. Small amounts (2-3 ⁇ M of each compound) were also detected in the blood.
- ESR electron spin resonance
- Example 22 Aqueous Solubility Data Table III: Solubility of Compound of Example 6 was determined at room temperature in various systems.
- 3-N-substituted-2.2-dimethylpropionic acids are prepared by the method described in U.S. Patent No. 5,475,013 to Talley et al, the content of which is incorporated herein by reference.
- NSAID nonsteroidal anti-inflammatory drugs containing carboxylic acid group
- DCC DMAP esterification method Starting material Chemical name (structure) Ketorolac or 5-Benzoyl-2,3-dihydro-lH- CCuH pyrrolizine-1 -carboxylic acid
- Example 65 Pharmacokinetics, Ocular Tissue Distribution, and Urinary Excretion of Total Radioactivity Following Single Topical Dose Administration of Compound 1 in Rabbits.
- the pharmacokinetics, ocular tissue distribution and urinary excretion of total radioactivity following a single topical dose administration of the tritiated hydrochloride of Compound 1 in rabbits was evaluated. Eighteen male New Zealand White (Harlan) rabbits, age 3-6 months, weight 2.1 to 3.0 kg were utilized.
- Experimental Design The experimental design was a randomized, single-treatment study in one group of rabbits administered a single topical application of [ 3 H]Compound 1- HC1 into both eyes. The group consisted of 6 subgroups of 3 animals.
- Mean concentration values of 3 H radioactivity were calculated and converted to equivalents per ml or g based on the measured specific activity and nominal concentration of the administered test article formulation as determined by oxidation. Concentrations of total radioactivity in blood and plasma, amount (% of dose) and concentration in ocular tissue and urine samples were determined. Elimination kinetics including blood, plasma, and tissue half-lives were calculated. Urinary excretion data were also tabulated. Statistical evaluation consisted of descriptive statistical analysis. Pharmacokinetics of radioactivity were evaluated by model independent analyses pending suitability of sample assay results. Non-truncated numerical values were used in the calculations.
- Example 66 Effect of Compound 1 or Tempol-H Treatment on Photochemical Retinal Damage in a Rabbit Model.
- the ability of light to produce retinal injury well below the levels capable of producing thermal damage has been termed photochemical retinal injury.
- the mechanism of action for photochemical retinal injury is believed to be the light induced production of free radicals.
- the ability of commonly used light sources in clinical ophthalmology to produce photochemical retinal injury is well recognized.
- the operating microscopes used in ophthalmic surgery have been shown to have the capability of producing retinal photochemical injury. This observation has been utilized to produce a model in the rabbit eye to test the ability of various agents to block photochemical retinal injury. It has been determined that opthalmoscopically visible retinal lesions are detectable after as little as 2.5 minutes of exposure to an operating microscope.
- the protocol set forth below is utilized to determine whether Compound 1 or tempol-H given via intravitreal injection has the ability to block the development of an ophthalmoscopically visible photochemical retinal lesion produced by a operating microscope.
- Materials and Methods One week prior to treatment, a baseline Fundus photograph and FA is performed on each animal. One day prior to being exposed to the light from a operating microscope, one eye of each animal receives an intravitreal injection of 0.1 cc of BSS® as a control and the fellow eye receives 0.1 cc of Compound 1 or Tempo-H in a BSS® vehicle.
- the animals are anesthetized with a IM injection of a 60%-40% mixture of ketamine hydrochloride lOOmg/ml and Xylazine 20mg/ml.
- a speculum is inserted into the eye receiving the injection, and the injection is performed using a 30g needle passed through the sclera just behind the limbus and angled to clear the lens, placing the tip in the mid vitreous cavity.
- the intraocular pressure is monitored using a hand-held Applanation tonometer. If necessary, a paracentesis is performed to return intraocular pressure to normal levels, prior to returning the animals to their cages.
- Compound 1 or tempol-H may be administered to the rabbit eye by multiple instillations of topical eye drops prior to the procedure.
- Forty eyes in 20 pigmented rabbits are exposed to the light from a Zeiss model OpMi 1 operating microscope for various periods of time up to one hour.
- the rabbits are anesthetized with a IM injection of a 60%-40% mixture of ketamine hydrochloride lOOmg/ml and Xylazine 20mg/ml.
- the rabbits are then positioned on a table; a lid speculum is inserted in the eye to be exposed.
- the pupil is dilated with tropicamide HCL 1%, and the cornea irrigated with BSS®.
- the light from the microscope is positioned 20 cm from the animal in a manner so that the light is centered and parallel to the eye.
- the light filaments are centered in sharp focus on the cornea.
- Forty-eight hours after exposure the animals are examined and a repeat Fundus photograph and FA performed.
- the animals are killed using standard techniques and selected eyes are harvested and stored in chilled glutaldehyde solution, for additional analyses.
- Example 67 Evaluation of Compound 1 or Tempol-H Incorporation into Retinal Tissue of Rabbits Following Intravitreous Injection
- the protocol set forth in this example utilizes scintillation technique to establish quantity and duration of Compound 1 or tempol-H incorporation into retinal tissue following intravitreous injection in the rabbit.
- the New Zealand White Rabbit is well characterized in experiments involving intravitreous injection as the large eye of the rabbit provides a suitable template for treatment administration (Hosseini et al., 2003, Lasers Surg. Med. 32: 265-270).
- New Zealand White Rabbit has been used extensively in experiments assessing drug uptake into retinal tissue via scintillation technique (Ahmed et al., 1987, J. Pharm. Sci. 76: 583-586).
- Materials and Methods Twenty-four New Zealand White Rabbits, all male, weighing between 2.5 and 3 kilograms, are used in this protocol. The rabbits are randomized into one of two treatment arms. Initially, rabbits are given baseline ocular exams to ensure that all eyes are free of irritation and infection. Following randomization and baseline exams, rabbits are anesthetized by subcutaneous injection of 100 mg/ml ketamine / 20 mg/ml xylazine. One drop of commercially available 0.5% proparacaine hydrochloride is applied to both eyes.
- Rabbits are then treated bilaterally by intravitreous injection in accordance with the masked randomization scheme shown below.
- Retinal tissue is ground into a slurry and dissolved in an alkali or quaternary ammonium compound. Scintillation readings are conducted to quantify the amount of Compound 1 or tempol-H present in the retinal tissue.
- Primary and secondary efficacy variables are for statistical significance. Two-sided nonparametric statistical tests are used, and p ⁇ 0.05 is considered statistically significant.
- Example 68 Efficacy of Tempol-H in Protection Against Photooxidative Processes in the Retinal Pigment Epithelium (RPE) Background: Although the etiology of atrophic age-related macular degeneration (AMD) is not fully understood, it is generally accepted that AMD begins with the death of retinal pigment epithelial cells, the degeneration of photoreceptor cells, and resultant loss of vision, occurring thereafter. There is a growing body of evidence linking the lipofuscin that accumulates in RPE with the death of these cells.
- AMD atrophic age-related macular degeneration
- A2E is converted into a mixture of compounds (A2E-epoxides) bearing epoxides of varying numbers. These highly reactive epoxides have been shown to damage the cell.
- the photochemical events provoked by the irradiation of A2E in RPE cells initiates cell death by way of a pathway that involves the participation of cysteine-dependent proteases (caspases) to cleave cellular substrates and that is modulated by the mitochondrial protein bcl-2.
- caspases cysteine-dependent proteases
- ARPE-19 cells that have accumulated A2E in culture were exposed to 430 +/- 20 nm light delivered from a halogen source. This wavelength of light is relevant since (i) the excitation maximum of A2E is approximately 430 nm, and (ii) light of this wavelength reaches the RPE in vivo while light of wavelengths longer than 400 nm are not absorbed by the cornea and lens. Cell death in blue light-illuminated A2E-laden RPE was compared with and without pre-treatment (24 hours) with tempol-H. The loss of cell viability was quantified by: 1.
- Cell viability was assessed 24 hours after blue light illumination. Triplicate wells were assayed in each of 2 experiments. 2.
- Two-color fluorescence assay in which the nuclei of all dead cells appear red due to staining by a membrane-impermeant dye (Dead Red nuclei acid stain, Molecular Probes) with the nuclei of all cells stained blue with DAPI.
- Cell viability was assessed 8 hours after blue light illumination. Replicates were assayed by counting cells within 5 microscopic fields within the area of illumination in each well and 3 wells were assayed per experiment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52380303P | 2003-11-20 | 2003-11-20 | |
PCT/US2004/039716 WO2005055926A2 (en) | 2003-11-20 | 2004-11-22 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1689354A2 true EP1689354A2 (en) | 2006-08-16 |
EP1689354A4 EP1689354A4 (en) | 2010-07-14 |
Family
ID=34676585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04812275A Withdrawn EP1689354A4 (en) | 2003-11-20 | 2004-11-22 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1689354A4 (en) |
JP (1) | JP2007527417A (en) |
KR (1) | KR20070040326A (en) |
CN (1) | CN101102770A (en) |
AU (1) | AU2004296738A1 (en) |
CA (1) | CA2546053A1 (en) |
IL (1) | IL175498A0 (en) |
WO (1) | WO2005055926A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
WO2006127592A2 (en) * | 2005-05-26 | 2006-11-30 | Othera Pharmaceuticals, Inc. | Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts |
WO2007100623A2 (en) * | 2006-02-22 | 2007-09-07 | Othera Holding, Inc. | Hydroxylamines and derivatives for the inhibition of complement activation |
EP2120942A2 (en) * | 2007-02-16 | 2009-11-25 | Othera Holding, Inc. | Drug resistance reversal in neoplastic disease |
AU2008218783A1 (en) * | 2007-02-22 | 2008-08-28 | Colby Pharmaceutical Company | Hydroxylamine compounds and methods of their use |
CA2707158A1 (en) * | 2007-11-28 | 2009-06-04 | Revision Therapeutics, Inc. | Modulators of ocular oxidative stress |
EP2080513A1 (en) * | 2008-01-16 | 2009-07-22 | Schraermeyer, Ulrich, Prof. Dr. rer. nat | Tetrahydropyridoethers for treatment of AMD |
CN102988331B (en) * | 2012-05-31 | 2015-02-04 | 管孝君 | Use of 2-mercapto-3-butanol in preparation of anti-lenticular opacity products |
EP3137116B1 (en) | 2014-04-30 | 2020-12-16 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
EP3180031A1 (en) | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
CN107106566A (en) * | 2014-10-31 | 2017-08-29 | 学校法人庆应义塾 | Phacosclerosis inhibitor |
EP3615086A4 (en) | 2017-04-27 | 2021-01-06 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
WO2018201124A1 (en) * | 2017-04-28 | 2018-11-01 | Case Western Reserve University | Antioxidants for use in ophthalmic surgery |
AU2018365250B2 (en) | 2017-11-10 | 2022-05-26 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
WO2021113662A2 (en) | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0327263A1 (en) * | 1988-01-29 | 1989-08-09 | PROCTOR, Peter H. | Hair growth stimulation with nitroxide and other radicals |
US5352442A (en) * | 1985-07-18 | 1994-10-04 | Proctor Peter H | Topical tempo |
US6001853A (en) * | 1996-01-26 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Hydroxylamine compositions for the prevention or retardation of cataracts |
WO2003096991A2 (en) * | 2002-05-17 | 2003-11-27 | Othera Pharmaceuticals, Inc. | Amelioration of the development of cataracts and other opthalmic diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1447095A (en) * | 1993-12-30 | 1995-07-17 | Arcturus Pharmaceutical Corporation | Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways |
US5981548A (en) * | 1994-11-15 | 1999-11-09 | Moreno Paolini | N-Hydroxypiperidines as superoxide radicals scavengers |
ATE428470T1 (en) * | 2000-06-29 | 2009-05-15 | Mei Co Ltd | REMEDIES FOR TREATING DISEASES OF THE OPTIC NERVE |
IT1320080B1 (en) * | 2000-10-25 | 2003-11-18 | Giuliani Spa | COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE. |
-
2004
- 2004-11-22 CN CNA2004800343580A patent/CN101102770A/en active Pending
- 2004-11-22 WO PCT/US2004/039716 patent/WO2005055926A2/en active Application Filing
- 2004-11-22 AU AU2004296738A patent/AU2004296738A1/en not_active Abandoned
- 2004-11-22 KR KR1020067012250A patent/KR20070040326A/en not_active Application Discontinuation
- 2004-11-22 EP EP04812275A patent/EP1689354A4/en not_active Withdrawn
- 2004-11-22 CA CA002546053A patent/CA2546053A1/en not_active Abandoned
- 2004-11-22 JP JP2006541459A patent/JP2007527417A/en active Pending
-
2006
- 2006-05-09 IL IL175498A patent/IL175498A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352442A (en) * | 1985-07-18 | 1994-10-04 | Proctor Peter H | Topical tempo |
EP0327263A1 (en) * | 1988-01-29 | 1989-08-09 | PROCTOR, Peter H. | Hair growth stimulation with nitroxide and other radicals |
US6001853A (en) * | 1996-01-26 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Hydroxylamine compositions for the prevention or retardation of cataracts |
WO2003096991A2 (en) * | 2002-05-17 | 2003-11-27 | Othera Pharmaceuticals, Inc. | Amelioration of the development of cataracts and other opthalmic diseases |
Non-Patent Citations (5)
Title |
---|
EL-REMESSY AZZA B ET AL: "Neuroprotective effect of (-)DELTA9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: Involvement of peroxynitrite." AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 5, 1 November 2003 (2003-11-01), pages 1997-2008, XP002584345 ISSN: 0002-9440 * |
See also references of WO2005055926A2 * |
WANG MIN ET AL: "Tempol, superoxide dismutase mimic, ameliorates light-induced retinal degeneration" RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, PJD PUBLICATIONS LTD, US, vol. 89, no. 3, 1 September 1995 (1995-09-01), pages 291-305, XP009114398 ISSN: 1078-0297 * |
WERMUTH C G ET AL: "The Practice of Medicinal Chemistry , DESIGNING PRODRUGS AND BIOPRECURSORS I: CARRIER PROGRUGS" PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1 January 1996 (1996-01-01), pages 671-696, XP002290286 * |
ZIGLER J SAMUEL JR ET AL: "Tempol-H inhibits opacification of lenses in organ culture." FREE RADICAL BIOLOGY & MEDICINE, vol. 35, no. 10, 15 November 2003 (2003-11-15), pages 1194-1202, XP002584344 ISSN: 0891-5849 * |
Also Published As
Publication number | Publication date |
---|---|
EP1689354A4 (en) | 2010-07-14 |
WO2005055926A3 (en) | 2006-12-07 |
CN101102770A (en) | 2008-01-09 |
AU2004296738A1 (en) | 2005-06-23 |
JP2007527417A (en) | 2007-09-27 |
WO2005055926A2 (en) | 2005-06-23 |
CA2546053A1 (en) | 2005-06-23 |
KR20070040326A (en) | 2007-04-16 |
IL175498A0 (en) | 2008-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004293105B2 (en) | Amelioration of macular degeneration and other ophthalmic diseases | |
US8383648B2 (en) | Amelioration of the development of cataracts and other ophthalmic diseases | |
US6060463A (en) | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | |
CA2461896C (en) | Injections for eye tissues containing drug bonded to polyethylene glycol | |
WO2005055926A2 (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
US7825134B2 (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
EP2156833A1 (en) | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient | |
US7589107B2 (en) | Amelioration of vitrectomy-induced cataracts | |
KR101891144B1 (en) | Lfa-1 inhibitor formulations | |
ZA200604402B (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
WO2010056710A1 (en) | Compositions and methods for treating eye diseases | |
US20080312283A1 (en) | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts | |
Adake | The Effect of Calcium Channel Blockers, Verapamil and Diltiazem Eye Drops on Intraocular Pressure in Rabbits and Comparative Study of Oral Amlodipine in Humans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060620 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK YU |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/445 20060101AFI20070116BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: OTHERA HOLDING, INC. |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 405/12 20060101ALI20100528BHEP Ipc: C07D 401/12 20060101ALI20100528BHEP Ipc: C07D 211/94 20060101ALI20100528BHEP Ipc: A61K 9/00 20060101ALI20100528BHEP Ipc: A61P 39/06 20060101ALI20100528BHEP Ipc: A61P 27/12 20060101ALI20100528BHEP Ipc: A61P 27/06 20060101ALI20100528BHEP Ipc: A61P 27/02 20060101ALI20100528BHEP Ipc: A61K 38/06 20060101ALI20100528BHEP Ipc: A61K 45/06 20060101ALI20100528BHEP Ipc: A61K 31/4525 20060101ALI20100528BHEP Ipc: A61K 31/198 20060101ALI20100528BHEP Ipc: A61K 31/145 20060101ALI20100528BHEP Ipc: A61K 31/445 20060101AFI20070116BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100615 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100914 |